Stockscreener 앱 받기
25.73
0.46%
-0.12
시간 외 거래:
25.73
전일 마감가:
$25.85
열려 있는:
$25.47
하루 거래량:
1.32M
Relative Volume:
0.78
시가총액:
$15.82B
수익:
$3.73B
순이익/손실:
$965.82M
주가수익비율:
16.62
EPS:
1.5481
순현금흐름:
$1.13B
1주 성능:
-3.16%
1개월 성능:
-10.97%
6개월 성능:
-9.02%
1년 성능:
+27.06%
1일 변동 폭
$25.34
$25.88
1주일 범위
$25.34
$26.84
52주 변동 폭
$17.23
$35.43
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
25.73 | 15.89B | 3.73B | 965.82M | 1.13B | 1.5481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 개시 | Wells Fargo | Overweight |
| 2026-02-17 | 재개 | Jefferies | Buy |
| 2026-02-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-04-01 | 다운그레이드 | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-04 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-08-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-15 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-12-06 | 업그레이드 | UBS | Neutral → Buy |
| 2023-11-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-11-08 | 업그레이드 | DNB Markets | Sell → Buy |
| 2023-10-18 | 개시 | Exane BNP Paribas | Underperform |
| 2023-09-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | 개시 | BTIG Research | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-31 | 개시 | UBS | Neutral |
| 2023-05-12 | 개시 | Morgan Stanley | Underweight |
| 2022-12-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-11-14 | 개시 | William Blair | Mkt Perform |
| 2022-11-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-06-24 | 개시 | BMO Capital Markets | Market Perform |
| 2022-05-02 | 개시 | Cowen | Market Perform |
| 2022-03-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-12-01 | 개시 | Berenberg | Sell |
| 2021-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | 개시 | Deutsche Bank | Buy |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | 다운그레이드 | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | 개시 | SVB Leerink | Mkt Perform |
| 2020-06-25 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | 개시 | Credit Suisse | Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-12 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-09-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | Morgan Stanley | Overweight |
| 2019-08-12 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Genmab Adr 주식(GMAB)의 최신 뉴스
Genmab ADR shows improved relative strength; still shy of benchmark - MSN
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches - Yahoo Finance
Alliancebernstein L.P. Has $335.96 Million Stock Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Genmab A/ S: The Biotech Stock Gen Z Is Quietly Watching - AD HOC NEWS
Russell Investments Group Ltd. Has $25.23 Million Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
First Trust Advisors LP Sells 82,922 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
GMAB Earnings History & Surprises | EPS & Revenue Results | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN
Correction to Company Announcement No. 13 of March 2, 2026 - GlobeNewswire Inc.
Stocks With Rising Relative Strength: Genmab ADR - Investor's Business Daily
Genmab ADR Shows Improved Relative Strength; Still Shy Of Benchmark - Investor's Business Daily
What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World
GENMAB A/S -SP ADR (NASDAQ:GMAB) Emerges as a Peter Lynch-Style GARP Investment - ChartMill
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales - Finviz
Genmab A/S (NASDAQ:GMAB) Given New $40.00 Price Target at HC Wainwright - Defense World
Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1 - Sahm
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Genmab A/S (NASDAQ:GMAB) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Genmab A/S Q4 Earnings Call Highlights - Yahoo Finance
Genmab A/S (NASDAQ:GMAB) Given Equal Weight Rating at Morgan Stanley - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Sees Significant Decrease in Short Interest - MarketBeat
279,932 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Cibc World Market Inc. - MarketBeat
Is the Options Market Predicting a Spike in Genmab Stock? - TradingView
H.C. Wainwright Bullish on Genmab A/S (GMAB) on Robust Sales for DARZALEX - Finviz
Envestnet Asset Management Inc. Purchases 60,336 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
RFG Advisory LLC Takes $1.30 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Where is Genmab A/S (GMAB) Headed According to Wall Street? - Finviz
Oppenheimer Asset Management Inc. Acquires 61,311 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth - ChartMill
Federated Hermes Inc. Makes New Investment in Genmab A/S Sponsored ADR $GMAB - MarketBeat
What is HC Wainwright’s Estimate for Genmab A/S Q4 Earnings? - Defense World
What is HC Wainwright's Estimate for Genmab A/S Q4 Earnings? - MarketBeat
EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) - Finviz
HC Wainwright Boosts Earnings Estimates for Genmab A/S - MarketBeat
GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment - Chartmill
Genmab A/S (NASDAQ:GMAB) Shares Gap DownHere's What Happened - MarketBeat
GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation - Chartmill
GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals - ChartMill
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Alkermes Stock Earns Technical Rating Upgrade - Investor's Business Daily
Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside - Finviz
Ascendis Pharma ADR shows rising price performance with jump to 83 RS rating - MSN
Genmab A/S (GMAB): A Bull Case Theory - Finviz
Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 - Investor's Business Daily
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Eagle Global Advisors LLC Buys 34,175 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab ADR Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Genmab A/S (NASDAQ:GMAB) Hits New 52-Week HighTime to Buy? - MarketBeat
Genmab A/S (OTCMKTS:GNMSF) Reaches New 1-Year HighShould You Buy? - MarketBeat
Genmab Adr (GMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):